カレントテラピー　30-11　サンプル page 28/36

このページは カレントテラピー　30-11　サンプル の電子ブックに掲載されている28ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
参考文献1）Fuster V, Ryden LE, Cannom DS, et al：ACC/AHA/ESC2006 guidelines for the management of patients with atrialfibrillation -executive summary：a report of the AmericanCollege of Cardiology/Ame....

参考文献1）Fuster V, Ryden LE, Cannom DS, et al：ACC/AHA/ESC2006 guidelines for the management of patients with atrialfibrillation -executive summary：a report of the AmericanCollege of Cardiology/American Heart Association TaskForce on Practice Guidelines and the European Society ofCardiology Committee for Practice Guidelines（WritingCommittee to Revise the 2001 Guidelines for the Managementof Patients with Atrial Fibrillation）. Eur Heart J 27：1979-2030, 20062）Gage BF, Waterman AD, Shannon W, et al：Validation ofclinical classification schemes for predicting stroke：resultsfrom the National Registry of Atrial Fibrillation. JAMA285：2864-2870, 20013）Oldgren J, Alings M, Darius H, et al；RE -LY Investigators：Risks for stroke, bleeding, and death in patients with atrialfibrillation receiving dabigatran or warfarin in relation to theCHADS2 score：a subgroup analysis of the RE -LY trial.Ann Intern Med 155：660 -667, 20114）Lip GY, Nieuwlaat R, Pisters R, et al：Refining clinical riskstratification for predicting stroke and thromboembolism inatrial fibrillation using a novel risk factor -based approach：the Euro Heart Survey on atrial fibrillation. Chest 137：263 -272, 20105）Sato H, Ishikawa K, Kitabatake A, et al：Low -dose aspirinfor prevention of stroke in low -risk patients with atrial fibrillation：Japanatrial fibrillation stroke trial. Stroke 37：447-451, 20066）Connolly S, Pogue J, Hart R, et al；ACTIVE Writing Groupof the ACTIVE Investigators：Clopidogrel plus aspirin versusoral anticoagulation for atrial fibrillation in the Atrialfibrillation clopidogrel trial with irbesartan for prevention ofvascular events（Active W）：A randomised controlled trial.Lancet 367：1903-1912, 20067）Connolly SJ, Ezekowitz MD, Yusuf S, et al；RE-LY SteeringCommittee and Investigators：Dabigatran versus warfarin inpatients with atrial fibrillation. N Engl J Med 361：1139-1151, 2009 and Erratum in：N Engl J Med 363：1877, 20108）Patel MR, Mahaffey KW, Garg J, et al；ROCKET AFInvestigators：Rivaroxaban versus warfarin in nonvalvularatrial fibrillation. N Engl J Med 365：883-891, 20119）G r a n g e r C B , A l e x a n d e r J H , M c M u r r a y J J , e t a l；ARISTOTLE Committees and Investigators：Apixaban versuswarfarin in patients with atrial fibrillation. N Engl J Med365：981 -992, 201110）Kaatz S, Kouides PA, Garcia DA, et al：Guidance on theemergent reversal of oral thrombin and factor Xa inhibitors.Am J Hematol 87（Suppl 1）：S141-145, 201290Current Therapy 2012 Vol.30 No.111190